Information Provided By: 
Fly News Breaks for March 19, 2019
AMAG
Mar 19, 2019 | 16:34 EDT
SunTrust analyst Gregg Gilbert initiated Amag Pharmaceuticals with a Neutral rating and a price target of $14, citing the company's focus to address areas of unmet need, such as "in Women's Healt hand the hospital setting". The analyst believes that the management is "steering the company in the right direction" to diversify its revenue base, but reserves a more constructive rating until more signs of regulatory and commercial execution. Gilbart adds that the "recent news on a negative clinical trial for Makena" is also giving him pause.
News For AMAG From the Last 2 Days
There are no results for your query AMAG
